跳至主要内容
临床试验/NCT01155401
NCT01155401已完成不适用

Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding

AstraZeneca1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2010年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
300
试验地点
1
主要终点
Number and percentage of patients with drug-induced upper gastrointestinal bleeding

研究概览

简要总结

The purpose of this study is to determine and analyse the incidence, severity, risk factors and routine management of acute drug-induced upper gastrointestinal bleeding (UGIB) in the population of Russian patients

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Established diagnosis of acute upper gastrointestinal bleeding, confirmed by presence of hematemesis/ coffee ground vomiting, melena, as well as other clinical or laboratory evidence of acute blood loss from the upper gastrointestinal tract
  • Written informed consent provided prior the start of participation in the study.

排除标准

  • Subjects who are unwilling or unable to provide informed consent.

结局指标

主要结局

Number and percentage of patients with drug-induced upper gastrointestinal bleeding

时间窗: About 1 year

次要结局

  • Number and percentage of patients with each symptom and each Forrest class of upper gastrointestinal bleeding(About 1 year)
  • Number and percentage of patients with each type of bleeding outcomes who received different types of hemostatic therapy(About 1 year)
  • Number and percentage of patients with concomitant diseases contributing to drug-induced upper gastrointestinal bleeding and those who receive NSAIDs, antiplatelet agents, anticoagulants, steroids or combination therapy(About 1 year)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验